glp-1 receptor agonist atrial fibrillation risk use cuts regardless of weight loss GLP‑1 Therapy Improves Atrial Fibrillation

Taking a GLP-1 medication plus a hypothetical GIP medication separately wouldnt necessarily produce the same effects as a designed dual agonist, and this approach hasnt been studied

Phase 1 Trials In a first-in-human, randomized, placebo-controlled, single ascending dose, phase 1 trial in healthy participants, retatrutide demonstrated a favourable safety profile (similar to other incretin-based therapies) and early signs of efficacy with dose-dependent WL [42]

These medications combine the effects of a GLP-1 receptor agonist with an agonist for GIP, another hormone produced by the small intestine

[DOI] [PMC free article] [PubMed] [Google Scholar] 53.Lee PH, Stockton MD, Franks AS